The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer.
A growing body of evidence consistently demonstrates the activity of bevacizumab, a monoclonal antibody that targets all isoforms of vascular endothelial growth factor (VEGF)-A, in combination with chemotherapy in the treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative, metastatic breast cancer. Clinical benefit has been limited to prolonged progression-free survival. As yet, combination regimens have failed to demonstrate a survival advantage. Emerging research suggests that single-nucleotide polymorphism in VEGF may predict response to combined therapy.
Keefe
Stephen M
SM
Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA. stephen.keefe@uphs.upenn.edu
Demichele
Angela
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A